Seagen Inc. (BOVESPA:S1GE34) Stock Price & Quote Analysis

S1GE34 Stock Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.

S1GE34 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 29.8% below our estimate of its fair value

Earnings are forecast to grow 62.81% per year

Risk Analysis

Shares are highly illiquid

My Notes

New

Notes are coming soon

Seagen Inc. Competitors

Blau Farmacêutica

BOVESPA:BLAU3

R$5.2b

Genmab

CPSE:GMAB

kr.173.9b

Hypera

BOVESPA:HYPE3

R$28.4b

Celltrion

KOSE:A068270

₩24.2t

Price History & Performance

Summary of all time highs, changes and price drops for Seagen
Historical stock prices
Current Share Price	US$34.86
52 Week High	US$48.36
52 Week Low	US$27.38
Beta	0.57
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-40.69%

Recent updates

Shareholder Returns

	S1GE34	BR Biotechs	BR Market
7D	0%	-0.1%	-2.9%
1Y	n/a	2.4%	-15.4%

Return vs Industry: Insufficient data to determine how S1GE34 performed against the BR Biotechs industry.

Return vs Market: Insufficient data to determine how S1GE34 performed against the BR Market.

Price Volatility

Is S1GE34's price volatile compared to industry and market?
S1GE34 volatility
S1GE34 Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.5%
10% most volatile stocks in BR Market	10.4%
10% least volatile stocks in BR Market	3.1%

Stable Share Price: Insufficient data to determine S1GE34's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine S1GE34's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1997	2,675	David Epstein	https://www.seagen.com

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases.

Seagen Inc. Fundamentals Summary

How do Seagen's earnings and revenue compare to its market cap?
S1GE34 fundamental statistics
Market Cap	R$131.53b
Earnings (TTM)	-R$3.27b
Revenue (TTM)	R$9.57b

13.7x

P/S Ratio

-40.2x

P/E Ratio

Is S1GE34 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
S1GE34 income statement (TTM)
Revenue	US$1.86b
Cost of Revenue	US$1.68b
Gross Profit	US$184.76m
Other Expenses	US$821.53m
Earnings	-US$636.76m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 15, 2023

Earnings per share (EPS)	-3.43
Gross Margin	9.91%
Net Profit Margin	-34.16%
Debt/Equity Ratio	0%

How did S1GE34 perform over the long term?

See historical performance and comparison

S1GE34 Stock Overview

Rewards

Risk Analysis

Seagen Inc. Competitors

BOVESPA:BLAU3

R$5.2b

CPSE:GMAB

kr.173.9b

BOVESPA:HYPE3

R$28.4b

KOSE:A068270

₩24.2t

Price History & Performance

Recent News & Updates

Seagen Inc. to Report Q4, 2022 Results on Feb 15, 2023

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Seagen Inc. Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma

Seagen Inc. Announces U.S. FDA Approval of New Indication for Adcetris® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

Seagen Inc. Revises Revenue Guidance for the Full Year of 2022

Seagen Inc. to Report Q3, 2022 Results on Oct 27, 2022

Recent updates

Seagen Inc. to Report Q4, 2022 Results on Feb 15, 2023

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Seagen Inc. Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma

Seagen Inc. Announces U.S. FDA Approval of New Indication for Adcetris® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma

Seagen Inc. Revises Revenue Guidance for the Full Year of 2022

Seagen Inc. to Report Q3, 2022 Results on Oct 27, 2022

Seagen Inc. Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer

Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (Enfortumab Vedotin-Ejfv) with KEYTRUDA((R) (Pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Seagen to Highlight Research in Urothelial and Colorectal Cancers At 2022 European Society for Medical Oncology (Esmo) Congress

Merck’s Reportedly Talks to Acquire Seagen Hit Snag, Threatening Mega Pharma Deal

Arbitrator Rules in Favor of Daiichi Sankyo Company, Limited in Dispute with Seagen Inc

Seagen Inc. Revises Earnings Guidance for the Year 2022

Seagen Inc. to Report Q2, 2022 Results on Jul 28, 2022

Merck Reportedly in Advanced Talks to Buy Seagen

Seagen Inc. Announces Full Results from the Pivotal Phase 2 MOUNTAINEER Trial, Which Showed TUKYSA (Tucatinib) in Combination with Trastuzumab

Merck Reportedly Pushes Forward with Potential Deal for Seagen

Merck, Other Suitors Reportedly Interested in Acquiring Seagen

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Takeda Pharmaceutical Company Limited and Seagen Inc. to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma

Seagen Inc. Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA(R) (tucatinib) in Combination with Trastuzumab in HER2-Positive Metastatic Colorectal Cancer

Seagen Announces Resignation of Clay Siegall as CEO

Seagen Inc., Annual General Meeting, May 13, 2022

Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence

Astellas Pharma Inc. and Seagen Inc. Announces European Commission Approves PADCEV™ (Enfortumab Vedotin) for Locally Advanced or Metastatic Urothelial Cancer

Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting

Seagen Inc. to Report Q1, 2022 Results on Apr 28, 2022

Astellas Pharma Inc. and Seagen Inc. Announce CHMP Confirms Positive Opinion for PADCEV™ (Enfortumab Vedotin) in Locally Advanced or Metastatic Urothelial Cancer

Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma

Seagen and Astellas Announce Initial Results of PADCEV (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

Seagen Inc. Provides Earnings Guidance for the Year 2022

ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma

Seagen Inc. Announces Executive Changes

Seagen Canada Announces Availability of PADCEV® to Treat Advanced Bladder Cancer

Seagen Inc. Announces Data from Phase I Clinical Trial Combining SEA-CD40

Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer

Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin)

Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib)

Seagen Inc. Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer

Japan’s MHLW Approves Astellas Pharma Inc. and Seagen Inc.'s PADCEV (enfortumab vedotin) for Advanced Urothelial Cancer

U.S. Food and Drug Administration Grants Approval to TIVDAK

Seagen Inc. and Genmab A/S Announce FDA Accelerated Approval for TIVDAK™ (Tisotumab Vedotin-Tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

Seagen Inc. Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting

Seagen Inc. and Astellas Pharma Inc. Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy

Seagen Inc. Provides Revenue Guidance for the Full Year of 2021

Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer

Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer

Seagen Inc. and Genmab A/S Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer

Seagen Inc. to Report Q4, 2020 Results on Feb 11, 2021

Seagen Inc. Announces Positive CHMP Opinion for Tukysa (Tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer

Seagen Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtual Annual Meeting 2020

Seagen Inc. announced that it has received $1 billion in funding from Merck Sharp & Dohme Corp.